#ADA26: Novo Nordisk targets 2030 launch for triple-G obesity shot

June 8, 2026 09:17 AM EDTUpdated 02:00 PM PharmaGLP-1 drugs No­vo Nordisk tar­gets 2030 launch for triple-G obe­si­ty shot Elizabeth Cairns Senior biopharma journalist The mol­e­cules known as triple-Gs — ag­o­nists of GLP-1, GIP and glucagon — are draw­ing at­ten­tion as da­ta build sug­gest­ing they could be the most ef­fec­tive class … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER